<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917237</url>
  </required_header>
  <id_info>
    <org_study_id>NICE-A</org_study_id>
    <nct_id>NCT04917237</nct_id>
  </id_info>
  <brief_title>Non-disabling Ischemic Cerebrovascular Event With Apathy</brief_title>
  <official_title>Non-disabling Ischemic Cerebrovascular Event With Apathy: A Prospective Registry Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The burden of non-disabling ischemic cerebrovascular events (NICE) is significantly&#xD;
      increased. However, few previous studies have focused on affective impairment after transient&#xD;
      ischemic attack (TIA) and minor stroke. Stroke survivors are often described as apathetic.&#xD;
      Even though post-stroke apathy (PSA) affects one in three stroke patients,it has not hitherto&#xD;
      received much attention. NICE-A is a prospective study aimed to explore the association&#xD;
      between baseline apathy and probable incident stroke in a population-based sample of TIA and&#xD;
      minor stroke adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transient ischemic attack (TIA) and acute minor ischemic stroke, are common and may leave&#xD;
      impermanent or mild neurological deficit, they are termed as non-disabling ischemic&#xD;
      cerebrovascular disease (NICE). TIA and minor stroke exhibit the common substantial risk&#xD;
      factors for early stroke recurrence and epidemiological characteristic, with approximately 10&#xD;
      to 20% of patients having a stroke within 3 months after the index event.&#xD;
&#xD;
      Previous studies has shown that post-stroke apathy (PSA) affects one in three stroke&#xD;
      patients, which is consistently associated with a worse level of functional recovery, poorer&#xD;
      overall health and poorer quality of life. However, still little is known about the&#xD;
      development of TIA and minor stroke patients with apathy. Thus, it is imperative to find the&#xD;
      relationships between baseline PSA and probable incident stroke in these patients.&#xD;
&#xD;
      NICE is an attractive researching area globally. According to the large quantities of NICE&#xD;
      patients in China and the low standardized therapeutic rate, the awareness of TIA and minor&#xD;
      stroke is largely insufficient. The purpose of the present NICE-A study is to establish the&#xD;
      prevalence, predictors and evolution of symptoms of PSA in TIA and minor stroke patients&#xD;
      during the first post-stroke year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2021</start_date>
  <completion_date type="Anticipated">June 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1 month</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>6 months</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>Death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke recurrence</measure>
    <time_frame>1 month</time_frame>
    <description>Ischemic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Ischemic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Ischemic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Ischemic stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>1 month</time_frame>
    <description>Cerebral hemorrhage and subaraclmoid hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>3 months</time_frame>
    <description>Cerebral hemorrhage and subaraclmoid hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>6 months</time_frame>
    <description>Cerebral hemorrhage and subaraclmoid hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Cerebral hemorrhage and subaraclmoid hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>1 month</time_frame>
    <description>Modified Rankin Scale ≥3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>3 months</time_frame>
    <description>Modified Rankin Scale ≥3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Modified Rankin Scale ≥3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Modified Rankin Scale ≥3</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Apathy</condition>
  <condition>Minor Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <condition>Stroke</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults patients (≥18 years) within 1 month of onset of a minor stroke (National Institute&#xD;
        of Health stroke scale, NIHSS≤3) and TIA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ≥18 years old Onset of a minor stroke (National Institute of Health stroke scale, NIHSS≤3)&#xD;
        and TIA elapsed time from last episode to registry &lt;1 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        patients who refused to participate in the research, and patients who failed to complete&#xD;
        the follow-up protocol.&#xD;
&#xD;
        patients with malignant tumors, or patients with severe liver or kidney disease, whose life&#xD;
        expectancy is less than 1 year.&#xD;
&#xD;
        patients who received endovascular or thrombolytic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoying Bi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoying Bi, MD, PhD</last_name>
    <phone>86-13795274796</phone>
    <email>bixiaoying2013@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bingying Du, MD, PhD</last_name>
    <phone>86-15800614142</phone>
    <email>15800614142@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bingying Du, PhD</last_name>
      <phone>15800614142</phone>
      <email>15800614142@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Bingying Du</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Apathy</keyword>
  <keyword>minor stroke</keyword>
  <keyword>Transient Ischemic Attack</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

